Effect of MEN 11467, a new tachykinin NK1 receptor antagonist, in acute rectocolitis induced by acetic acid in guinea-pigs.
The aim of this study was to evaluate the effect of MEN 11467 (1R,2S)-2-N[1(H)indol-3-yl-carbonyl]-1-N{N-(p-tolylacetyl)-N-(meth yl)-D-3(2-Naphthyl)alanyl}diaminocyclohexane), a new potent tachykinin NK1 receptor antagonist, in an experimental model of acute rectocolitis induced by an enema with 7.5% acetic acid in guinea-pigs. This effect was compared to that of mesalazine (5-amino-2-hydroxybenzoic acid). The injury was quantified visually by using a macroscopic injury score and histologically by using a necrosis score. In addition, changes in myeloperoxidase activity, a marker for neutrophil infiltration, and plasma protein extravasation were evaluated. The injury caused by 7.5% acetic acid was mild, affecting the superficial layers and producing a strong edema of the submucosa. A single administration of MEN 11467 (0.3-10 mg/kg s.c., I h before acetic acid) reduced the macroscopic damage and necrosis score and the increase in plasma protein extravasation induced by 7.5% acetic acid in the early acute phase of the injury (death at 2.5 h). Mesalazine (100 mg/kg p.o., 1 h before) reduced the macroscopic score but not the plasma protein extravasation. Repeated administration of MEN 11467 (1-3 mg/kg s.c., -1, +6 and +23 h after 7.5% acetic acid) reduced the macroscopic score and myeloperoxidase activity but not the plasma protein extravasation induced in the late phase of acute injury (death at 24 h). At this time mesalazine markedly reduced the macroscopic score, myeloperoxidase activity and plasma protein extravasation induced by 7.5% acetic acid. These results suggest a greater involvement of tachykinin NK1 receptors in the early phase than in the late phase of colonic inflammation in response to chemical injury.
Cutrufo
C
C
Menarini Ricerche spa, Department of Pharmacology, Pomezia Rome, Italy.
Evangelista
S
S
Cirillo
R
R
Ciucci
A
A
Conte
B
B
Lopez
G
G
Manzini
S
S
Maggi
C A
CA
D019342:Acetic Acid / Q000009:adverse effects; D000208:Acute Disease; D000285:Administration, Rectal; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001798:Blood Proteins / Q000032:analysis*; D003514:Cyclohexylamines / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004347:Drug Interactions; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000209:etiology*; D006168:Guinea Pigs; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D019804:Mesalamine / Q000494:pharmacology; D009195:Peroxidase / Q000378:metabolism*; D011350:Proctocolitis / Q000139:chemically induced / Q000188:drug therapy*; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001798:Blood Proteins; D003514:Cyclohexylamines; D007211:Indoles; C121095:MEN 11467; D018039:Receptors, Tachykinin; D019804:Mesalamine; D009195:Peroxidase; D019342:Acetic Acid